Biofilms: survival mechanisms of clinically relevant microorganisms

dc.contributor.authorDonlan, R. M.
dc.contributor.authorCosterton, J. William
dc.date.accessioned2017-08-21T20:10:51Z
dc.date.available2017-08-21T20:10:51Z
dc.date.issued2002-04
dc.description.abstractThough biofilms were first described by Antonie van Leeuwenhoek, the theory describing the biofilm process was not developed until 1978. We now understand that biofilms are universal, occurring in aquatic and industrial water systems as well as a large number of environments and medical devices relevant for public health. Using tools such as the scanning electron microscope and, more recently, the confocal laser scanning microscope, biofilm researchers now understand that biofilms are not unstructured, homogeneous deposits of cells and accumulated slime, but complex communities of surface-associated cells enclosed in a polymer matrix containing open water channels. Further studies have shown that the biofilm phenotype can be described in terms of the genes expressed by biofilm-associated cells. Microorganisms growing in a biofilm are highly resistant to antimicrobial agents by one or more mechanisms. Biofilm-associated microorganisms have been shown to be associated with several human diseases, such as native valve endocarditis and cystic fibrosis, and to colonize a wide variety of medical devices. Though epidemiologic evidence points to biofilms as a source of several infectious diseases, the exact mechanisms by which biofilm-associated microorganisms elicit disease are poorly understood. Detachment of cells or cell aggregates, production of endotoxin, increased resistance to the host immune system, and provision of a niche for the generation of resistant organisms are all biofilm processes which could initiate the disease process. Effective strategies to prevent or control biofilms on medical devices must take into consideration the unique and tenacious nature of biofilms. Current intervention strategies are designed to prevent initial device colonization, minimize microbial cell attachment to the device, penetrate the biofilm matrix and kill the associated cells, or remove the device from the patient. In the future, treatments may be based on inhibition of genes involved in cell attachment and biofilm formation.en_US
dc.identifier.citationDonlan, R.M., and J.W. Costerton, "Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms," Clin. Microbiol. Rev., 15(2):1 (2002).en_US
dc.identifier.issn0893-8512
dc.identifier.urihttps://scholarworks.montana.edu/handle/1/13560
dc.titleBiofilms: survival mechanisms of clinically relevant microorganismsen_US
dc.typeArticleen_US
mus.citation.extentfirstpage167en_US
mus.citation.extentlastpage193en_US
mus.citation.issue2en_US
mus.citation.journaltitleClinical Microbiology Reviewsen_US
mus.citation.volume15en_US
mus.data.thumbpage7en_US
mus.identifier.categoryEngineering & Computer Scienceen_US
mus.identifier.doi10.1128/cmr.15.2.167-193.2002en_US
mus.relation.collegeCollege of Engineeringen_US
mus.relation.departmentCenter for Biofilm Engineering.en_US
mus.relation.departmentChemical & Biological Engineering.en_US
mus.relation.departmentChemical Engineering.en_US
mus.relation.researchgroupCenter for Biofilm Engineering.en_US
mus.relation.universityMontana State University - Bozemanen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
02-014_Biofilms_survival_mechanisms_.pdf
Size:
3.38 MB
Format:
Adobe Portable Document Format
Description:
Biofilms: survival mechanisms of clinically relevant microorganisms (PDF)

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
826 B
Format:
Item-specific license agreed upon to submission
Description:
Copyright (c) 2002-2022, LYRASIS. All rights reserved.